Glenmark Pharma reported an 86% YoY drop in Q1FY26 net profit to Rs 46.9 crore, even as revenue stayed flat at Rs 3,264 crore. EBITDA slipped 1.4%, with margins narrowing to 17.7%. India sales rose modestly, while North America saw sequential growth. The company highlighted progress in its Ryaltris, QiNHAYO and Winlevi pipelines. Shares closed slightly higher.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets